Co-financing policy

in page functions
 

Co-financing means that countries contribute to the cost of Gavi-supported vaccines by procuring some of the required vaccine doses with non-Gavi funds

In June 2015, the Board approved an update to the co-financing policy that will take effect in January 2016. The new policy includes limited changes to the calculations for co-financing obligations for phase 1 (intermediate) countries. This page will be updated to reflect those new changes in January 2016, but currently describes the policy in effect through the end of 2015.

What is the purpose of Gavi's co-financing policy?

The co-financing policy encourages countries to plan for financially sustainable immunisation programmes in preparation for phasing out Gavi support for new vaccines. Recognising that the time frame for attaining financial sustainability varies across countries, the intermediate objective for the world's low-income countries is enhanced country ownership of vaccine financing.

When is the co-financing policy applied and how does it work?

Since 2007, all countries applying to Gavi for new vaccine support have been required to co-finance a portion of the cost of the requested vaccines.

The only exceptions from co-financing are vaccines for Inactivated Poliovirus (IPV), measles second dose, meningitis A, yellow fever preventive campaigns, human papilloma virus (HPV) demo and measles-rubella catch-up campaign.

The co-financing requirements are established on the basis of a country's income and are calculated on a per dose level. The three country groupings and their related co-financing requirements established under the co-financing policy are listed below.

Country co-financing groups

Country Group 

GNI per capita threshold 

Co-financing requirement 

Low Income Countries
(Initial Self-financing)

GNI per capita at or below the World Bank low-income threshold

(currently ≤$1,045)

$0.20 per dose

(no annual increase)

Intermediate Countries
(Phase 1 or Preparatory Transition)

GNI per capita above the World Bank low-income threshold but at or below the Gavi eligibility threshold

(currently >$1,045 to ≤$1,580)

Starts at $0.20 per dose and increases 15% annually

Graduating Countries
(Phase 2 or Accelerated Transition)

GNI per capita above the Gavi eligibility threshold

(currently $1,580)

Starts at an additional 20% of the difference between the projected price of the vaccine in the year Gavi support ends and the co-financing amount per dose paid in the preceding year, and increases linearly over four years to reach the projected price

Under the new eligibility and transition policy effective July 2015, country group labels have been revised. However, co-financing requirements remain the same until the new co-financing policy takes effect in January 2016. 

When was the co-financing policy approved and when will it be updated?

Gavi has applied a co-financing policy since 2007. Gavi's revised co-financing policy was approved by the Gavi Board in December 2010 and the new co-financing obligations took effect in 2012. The policy is scheduled for review and, if required, updating in 2015.

Co-financing, an investment in our children

Co-financing new vaccines is central to Rwanda’s plans to meet MDG 4 on reducing child mortality, says Dr. Agnes Binagwaho, Permanent Secretary at Rwanda's Health Ministry.


Viewpoint

Agnes Binagwaho

+4 million

Gavi support had contributed to immunising more than four million children against rotavirus diarrhoea by the end of 2013.

WHO/UNICEF

More facts...

close icon

modal window here